Shenzhen Dartmon Biotechnology Co.,Ltd.

06/05/2026

✨The 31st Congress of Chinese Society of Pathology and 15th Annual Meeting of Chinese Pathologists concluded successfully. ✨

Dartmon’s new products - and - garnered great attention from pathologists and industry partners! 👍👍👍

We engaged in in-depth discussions with clients and peers, expanded cooperation channels and secured high-quality potential leads. Grateful for all customer visits and the hard work of team.

We will continue to optimize our products and services for mutual win-win development!👏👏👏

06/05/2026

💎 💎 💎 Dartmon After-sales Service: The Core Confidence in Industry Competition
✨ ✨ ✨ In the pathology industry, the value of products is reflected not only in core performance and innovative design, but also embodied in the after-sales service system throughout the entire life cycle. For cross-border cooperation, after-sales service serves as a crucial link connecting suppliers with overseas markets. They directly determine the quality of customer experience, the accumulation of brand reputation, and the stability of long-term partnerships.

💎 💎 💎 Ultimate Dedication: Build Service Barriers with Sincere Attention
✨ ✨ ✨ As a supplier with years of in-depth expertise in the pathology industry, Dartmon has always placed after-sales service at a strategic level. From building a professional service team to establishing a global service response network; from developing multilingual, refined technical manuals, to creating an integrated online and offline training system, every initiative demonstrates our ultimate pursuit of high-quality after-sales services.

💎 💎 💎 Cooperation for Win-Win Results
✨ ✨ ✨ Dartmon delivered specialized training for engineers from our distributor. All the engineers boast years of experience and demonstrated strong initiative in learning. Focusing on core product technologies, installation and commissioning procedures, solutions to common faults, and advanced maintenance skills, Dartmon’s engineers provided systematic lectures and on-site demonstrations. This training has laid a solid foundation for the efficient delivery of after-sales services in the future. 💪 💪 💪

06/05/2026

🧐 🧐 🧐 Langerhans cell histiocytosis ( ) is a rare condition characterized by abnormal growth of the Langerhans cells. The proliferation of these cells leads to the formation of tumors called granulomas, which can then invade the bones and cause pain, inflammation and (in some instances) bone fracture. The disease is most commonly seen in children younger than 15 years of age; however, it has been observed in other age groups too.

📌 📌 📌 The exact etiology of LCH is unknown; however, somatic mutations in the gene have been identified in the majority of the patients. In a nutshell, BRAF gene encodes a protein called B-Raf, which is involved in transmitting growth signals to the nucleus of the cell. Consequently, somatic mutations in the BRAF gene lead to increased production of the B-Raf protein, which ultimately causes uncontrollable cell proliferation.

🔬 🔬 🔬 The histological features of LCH are variable and influenced by the age of lesions and their location. Generally speaking, on microscopy, cells are oval or round with a nuclear groove resembling a coffee bean. LCH coalesces as an eosinophilic granuloma, owing to the influx of eosinophils, macrophages, T cells, and multinucleated cells. Immunostaining highlights the expression of CD1a, Langerin (CD207), and S100.

📢 📢 📢 (CD207) is a type II transmembrane protein which is encoded by the CD207 gene in humans. It is a main part of Birbeck granules. Langerin is C-type lectin receptor on Langerhans cells (LCs). It is the most specific marker for Langerhans cells and is functionally involved in antigen uptake.

📣 📣 📣 (Cluster of Differentiation 1a) is a human protein encoded by the CD1A gene. CD1a is a β2 microglobulin associated transmembrane glycoprotein of the CD1 family that presents lipid and glycolipid antigens to T cells and serves as a diagnostic marker for Langerhans cells and selected immature T cell neoplasms.

💎 Dartmon Langerin/CD207 antibody 💎
▪️ Clone: DA175
▪️ Cat. No. : DMRD0216
▪️ Usage pattern: Manual or device utilization
▪️ Ready-to-use: 3ml, 6ml, 10ml
▪️ Concentrated: 0.1ml, 0.5ml, 1ml

💎 Dartmon CD1a antibody 💎
▪️ Clone: DA016
▪️ Cat. No. : RMB1A055
▪️ Usage pattern: Manual or device utilization
▪️ Ready-to-use: 3ml, 6ml, 10ml
▪️ Concentrated: 0.1ml, 0.5ml, 1ml

06/05/2026

🎉 🎉 🎉 IHC Antibody Selection Guide: A Practical Protocol Applicable to 90% of Clinical Tumor Diagnostics | Episode 2️⃣ 🎉 🎉

🌺 🌺 🌺 This guide summarizes the key diagnostic antibodies for common clinical tumor types, providing an efficient and reliable selection reference for pathology laboratories and research institutions. 🌺 🌺 🌺

💥 💥 💥 Dartmon provides over 400 high-quality IHC antibodies, covering 90% of common clinical tumor testing scenarios. Using them with secondary antibodies from Dartmon can improve staining stability by 30% 💥 💥 💥

✅ Click here to explore our 2nd episode: Prostate Cancer IHC Antibody Guide ✅

With regard to men, carcinoma of the prostate gland represents the second most common cancer, after lung cancer. Carcinoma of prostate gland is associated with advanced age, genetics factor smokers, obese individuals, and due to endogenous factors.

06/05/2026

📌 Anaplastic lymphoma kinase (ALK) is an enzyme that in humans is encoded by the ALK gene. Normal ALK is expressed only in embryonic nerves and plays a role in nervous system development. As adults, ALK is mostly silent and rarely express themselves.

💥 However, in tumors, due to ALK gene rearrangements, point mutations, and amplification, ALK kinase activity is permanently and uncontrolled, driving tumor development.

‼️ ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is a type of T-cell lymphoma, most commonly seen in children and young adults. Due to a t(2;5) chromosome translocation, an NPM-ALK gene fusion occurs, resulting in persistent ALK activation and driving lymphoma development.

‼️ ALK fusion-positive non-small cell lung cancer (NSCLC) occurs in 3%–5% of NSCLC patients. Due to an inversion of an internal segment of chromosome 2, an EML4-ALK gene fusion occurs, forming a constitutively activated kinase that strongly drives the tumor.

📌 ALK is an important target across cancer types, and it must be detected in lymphoma and lung cancer. This guides targeted therapy.

📢 We, , offer antibody to aid in the diagnosis of tumors.

💎 Dartmon ALK antibody 💎
▪️ Clone: DA002
▪️ Cat. No. : RMB1A001
▪️ Usage pattern: Manual or device utilization
▪️ Ready-to-use: 3ml, 6ml, 10ml

06/05/2026

❓ What is Low-grade osteosarcomas 🤔
🔔 is a malignant bone-forming tumor that produces osteoid or immature bone, but behaves far less aggressively than its high-grade counterpart. Although slow-growing, it remains a malignant tumor requiring surgery.
🔔 Under a microscope, these cells look more like normal bone cells and have few dividing cells. These tumors are more likely to form on the outermost layer of the bone covering, called the periosteum, or on the surface of the bone (periosteal). In rare cases they can occur in the center of the bone (low-grade central osteosarcoma).

📢 Low-Grade Osteosarcomas vs. Benign Bone Lesions 😶
🔔 These two categories can be notoriously difficult to distinguish — both radiographically and histologically — which is precisely why IHC and careful pathological analysis matters.

‼️ MDM2 / CDK4 Amplification (the key molecular differentiator)
✅ Low-grade central osteosarcoma and parosteal osteosarcoma characteristically show MDM2 and CDK4 gene amplification — detectable by FISH or IHC.
✅ Benign bone lesions are negative for MDM2/CDK4 amplification.
✅ This is arguably the single most important distinguishing marker in difficult cases.

💥 MDM2 & CDK4 IHC Expression in Low-Grade Osteosarcoma
🔔 Low-grade osteosarcoma shows nuclear positivity for MDM2 and CDK4 antibodies, with moderate to strong staining intensity. The positive staining can be seen in majority (around 80-95%) of low-grade osteosarcomas. If a low-grade osteosarcoma dedifferentiates into high-grade, MDM2/CDK4 amplification is retained in the high-grade component — so these markers remain useful even in transformed tumors.

⭐ We, , provide and antibodies to assist in the differential diagnosis of low-grade osteosarcoma and benign bone lesions.

💎 Dartmon MDM2 antibody
🔹 Clone: DA080
🔹 Cat. No. : MMB1A074
🔹 Usage pattern: Manual or device utilization
🔹 Ready-to-use: 3ml, 6ml, 10ml

💎 Dartmon CDK4 antibody
🔹 Clone: DA133
🔹 Cat. No. : DMRDB158
🔹 Usage pattern: Manual or device utilization
🔹 Ready-to-use: 3ml, 6ml, 10ml

06/05/2026

📢 At , we provide IHC-based diagnostic solutions for colorectal cancer — that help pathologists see what the eye alone cannot. ⭐ When a biopsy is taken, our technology helps reveal the molecular fingerprint of the tissue: 📣 identifying cancer subtypes, guiding treatment decisions, and ultimately putting the right therapy in the right patient's hands faster. 💎

✅ Clike to check Dartmon's Colorectal Cancer antibody ✅ https://lnkd.in/gbBeEeC9

Colorectal cancer usually develops from adenomatous polyps, undergoing the progression from abnormal proliferative changes to canceration, with a relatively long onset cycle. The entire process, from hyperplastic polyps to precancerous adenomas and then to cancer, takes approximately 7 to 15 years.

06/05/2026

📌 h-Caldesmon
✨ h‑Caldesmon is a calmodulin‑ and actin‑binding protein that is specifically expressed mainly in smooth muscle cells and smooth muscle‑derived tumors. By binding to intracellular actin filaments and myosin, it effectively inhibits excessive contraction of smooth muscle, thereby maintaining the homeostasis of cell tension and motility.

📌 h-Caldesmon and Cancer
✨ In most cancers (e.g., breast, colorectal, and liver cancer), the expression of h‑Caldesmon is downregulated or its activity is lost, resulting in a weakened inhibitory effect on cell migration. It removes the constraints on cell movement, thereby significantly enhancing the invasion and metastatic potential of tumor cells.
✨ In certain tumors (e.g., pancreatic cancer and mesothelioma), h‑Caldesmon expression is conversely upregulated and it is associated with tumor angiogenesis, drug resistance, and poor prognosis.

📌 Application of h‑Caldesmon for Pathological Diagnosis
✨ h-Caldesmon is a marker for the identification of smooth muscle. Diffuse and strong positivity for h‑Caldesmon is one of the evidences supporting the diagnosis of leiomyoma or leiomyosarcoma. In the differential diagnosis of leiomyosarcoma versus myofibroblastic proliferative or neoplastic lesions such as myofibroblastic sarcoma and nodular fasciitis, positivity for h‑Caldesmon is indicative of leiomyosarcoma.

📌 The combined use of h‑Caldesmon and CD10 helps to differentiate uterine mesenchymal tumors
✨ Uterine smooth muscle tumors (leiomyoma / leiomyosarcoma) typically show strong positivity for h‑Caldesmon, but they are negative or only focally weakly positive for CD10.
✨ Endometrial stromal sarcomas characteristically exhibit diffuse positivity for CD10, but they are negative for h‑Caldesmon.

💎 antibody
◾ Cat. No.: MMB1A112
◾ Ready to use: 3ml, 6ml, 10ml
◾ CE certification and FDA approval

06/05/2026

❓ What is ❓
✅ BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf.

❓ What is BRAF-V600E ❓
✅ More than 30 mutations of the BRAF gene associated with human cancers have been identified. In 90% of the cases, thymine is substituted with adenine at nucleotide 1799. This leads to valine (V) being substituted for by glutamate (E) at codon 600 (now referred to as V600E) in the activation segment that has been found in human cancers.

📢 The carcinogenic mechanism of BRAF-V600E 📌
✅ The V600E mutation causes constitutive activation of BRAF protein kinase activity, enabling sustained activation of downstream signaling pathways independently of upstream stimuli, ultimately leading to aberrant cell proliferation, resistance to apoptosis, and tumor progression.

📢 The BRAF V600E mutation is widely present in a variety of malignant tumors 📌
✅ This mutation has been widely observed in papillary thyroid carcinoma, colorectal cancer, melanoma and non-small-cell lung cancer.
🔷 High-prevalence tumors: Papillary thyroid carcinoma (approximately 45%), cutaneous melanoma (40%–60%), and low-grade/serous borderline ovarian carcinoma (approximately 35%).
🔷 Moderate-prevalence tumors: Colorectal cancer (5%–15%).
🔷 Low-prevalence tumors: Non-small cell lung cancer (1%–3%).
🔹 This mutation is also detected in some benign precursor lesions (e.g., colonic serrated adenomas), suggesting that it may represent an early event in tumorigenesis and drive malignant transformation.

📢 Detection of BRAF V600E mutation by immunohistochemistry (IHC)
✅ IHC is a widely used clinical detection method for BRAF V600E mutation. In positive tumor tissue sections, tumor cells typically show diffuse and uniform cytoplasmic staining with the specific BRAF V600E antibody; the staining intensity is generally consistent, and non-tumor cells (such as stromal cells or inflammatory cells) usually do not exhibit specific staining, serving as internal negative controls.

💎 BRAF antibody 💎
◾ Cat. No.: RMB1A106
◾ Ready to use: 3ml, 6ml, 10ml
◾ Concentrated: 0.1ml, 0.5ml, 1ml
💎 CE certification and FDA approval 💎

06/05/2026

🎉 🎉 🎉 10 Units of Auréos Series Fully Automatic IHC/ISH Stainers Successfully Delivered to Our International Partners. 🌺 🌺 🌺

✨ ✨ ✨ Kicking off the new year with a significant order, this delivery underscores our clients’ trust in the quality, reliability, and innovation of the Auréos Series. It also marks a meaningful step in strengthening our global collaboration—moving forward together toward shared success. 🎊 🎊 🎊

💎 💎 💎 We remain committed to empowering pathology laboratories, healthcare professionals, and distributors worldwide with high-performance IHC staining solutions and dedicated support.